New Strong Sell Stocks for September 13th · 5d ago
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates · 09/08 11:45
BRIEF-Affimed Reports Second Quarter 2021 Financial Results · 09/08 10:40
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
AFM13 monotherapy: Enrollment is on track and expected to be completed in the first half of 2022.AFM13 combination with NK cells: All three dose escalation cohorts are fully enrolled with no dose limiting toxicities observed; additional patients are being ...
GlobeNewswire · 09/08 10:30
-- Earnings Flash (AFMD) AFFIMED N.V. Posts Q2 Revenue $9.71M, vs. Street Est of $9.03M
MT Newswires · 09/08 08:52
Affimed's Q2 Loss Flat, Revenue Rises
MT Newswires · 09/08 07:20
Affimed to Present at Upcoming Investor Conferences
Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that management will present and host one-on-one meetings at the following investor conferences du...
GlobeNewswire · 08/26 10:30
Sio Capital Management, LLC Buys Aveanna Healthcare Holdings Inc, Amgen Inc, Integer Holdings ...
GuruFocus News · 08/24 15:38
Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021
Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a confe...
GlobeNewswire · 08/23 10:30
HealthCor Management, L.P. Buys Petco Health and Wellness Co Inc, Regeneron Pharmaceuticals ...
GuruFocus News · 08/18 20:38
Will Affimed N.V. (AFMD) Report Negative Q2 Earnings? What You Should Know · 08/03 19:00
Affimed Announces Publication of Comprehensive Preclinical Data Demonstrating the Therapeutic Potential of AFM24 in EGFR-expressing Tumors
AFM24 is an innate cell engager with a novel and distinctive mechanism of action, designed to address the need of broader patient populations than current EGFR-targeting treatments.Preclinical data demonstrate AFM24’s activation of the innate immune system...
GlobeNewswire · 07/30 10:30
15 Stocks that Will Double In 2021
In this article, we discuss the 15 stocks that will double in 2021. If you want to skip our detailed analysis of these stocks, go directly to the 5 Stocks that Will Double In 2021. The economy of 2020 was closely linked to the COVID-19 pandemic. However, t...
Insider Monkey · 07/29 21:31
NRXP, PDD, ACOR and IPA among after-hours movers
Gainers: [[NRXP]] +10.1%. [[PDD]] +6.6%. [[TLSA]] +6.3%. [[AFMD]] +4.4%. [[UXIN]] +3.8%.Losers: [[ACOR]] -3.8%. [[IPA]] -2.8%. [[SNCR]] -2.5%. [[PRVB]] -2.3%. [[INCY]] -3.3%.
Seekingalpha · 07/23 21:40
Hedge Funds Are Crazy About Affimed NV (AFMD)
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshl...
Insider Monkey · 07/19 23:15
Analyzing Affimed's Unusual Options Activity
Shares of Affimed (NASDAQ:AFMD) saw some unusual options activity on Tuesday. Following the unusual option alert, the stock price moved down to $6.77.
Benzinga · 07/13 15:17
Unusual Options Activity Insight: Affimed
On Thursday, shares of Affimed (NASDAQ:AFMD) saw unusual options activity. After the option alert, the stock price moved down to $7.49.
Benzinga · 07/01 15:42
The Daily Biotech Pulse: Spero Spikes On Pfizer Investment, FDA Nod For Jazz, Orchard Signs Licensing Deal, Acumen Pharma Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 30)
Benzinga · 07/01 12:06
Affimed posts Q1 topline beat, provides cash runway update
Affimed (AFMD) posted first-quarter revenue that beat Wall Street estimates, and said that it expects the company's cash and cash equivalents to support operations into the second half of 2023.The company's
Seekingalpha · 07/01 11:33
BRIEF-Affimed Reports Q1 2021 Financial Results · 07/01 10:36
Webull provides a variety of real-time AFMD stock news. You can receive the latest news about Affimed through multiple platforms. This information may help you make smarter investment decisions.
About AFMD
Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company's product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body's own immune system to fight tumor cells. Its pipeline includes AFM13, AFM13 + adoptive NK cells, AFM13 + anti-PD-1, AMF24, AMF26, AMF28 and AMF32. The Company is enrolling patients into a registration-directed study of AFM13 for CD30-positive relapsed/refractory peripheral T-cell Lymphoma and into a Phase 1/2a dose escalation/expansion study of AFM24 for the treatment of advanced EGFR-expressing solid tumors. Its preclinical product candidates include AMF26 for treating multiple myeloma, as well as AMF28 and AMF32, for treating of multiple tumor targets. In addition, the Company collaborates with Genentech to develop and commercialize certain product candidates for treating multiple cancers.